Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1α Stability in Aerobic Conditions

Cell Metabolism

Volumn 24, Issue 5, 2016, Pages 740-752

  Burr, Stephen P ^a   Costa, Ana S H ^b   Grice, Guinevere L ^a   Timms, Richard T ^a   Lobb, Ian T ^a   Freisinger, Peter ^c   Dodd, Roger B ^a   Dougan, Gordon ^d,e   Lehner, Paul J ^a   Frezza, Christian ^b   Nathan, James A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Kreiskliniken Reutlingen   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; LIPOIC ACID SYNTHASE; MITOCHONDRIAL PROTEIN; OXOGLUTARATE DEHYDROGENASE; SYNTHETASE; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROLINE; SULFURTRANSFERASE;

AEROBIC METABOLISM; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; HUMAN CELL; LIPOYLATION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STABILITY; CELL LINE; GENETICS; HELA CELL LINE; HOMOZYGOTE; HYDROXYLATION; METABOLISM;

AEROBIOSIS; CELL LINE; GENETIC TESTING; GERM-LINE MUTATION; GLUTARATES; HELA CELLS; HOMOZYGOTE; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KETOGLUTARATE DEHYDROGENASE COMPLEX; LIPOYLATION; MITOCHONDRIAL PROTEINS; PROLINE; PROTEIN STABILITY; SULFURTRANSFERASES;

EID: 84994672095     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.09.015     Document Type: Article

References (31)

1. Ahting, U., Mayr, J.A., Vanlander, A.V., Hardy, S.A., Santra, S., Makowski, C., Alston, C.L., Zimmermann, F.A., Abela, L., Plecko, B., et al. Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency. Front. Genet., 6, 2015, 123.
2. Baker, P.R. 2nd, Friederich, M.W., Swanson, M.A., Shaikh, T., Bhattacharya, K., Scharer, G.H., Aicher, J., Creadon-Swindell, G., Geiger, E., MacLean, K.N., et al. Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5. Brain 137 (2014), 366–379.
3. Benita, Y., Kikuchi, H., Smith, A.D., Zhang, M.Q., Chung, D.C., Xavier, R.J., An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 37 (2009), 4587–4602.
4. Bruick, R.K., McKnight, S.L., A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001), 1337–1340.
5. Carette, J.E., Guimaraes, C.P., Varadarajan, M., Park, A.S., Wuethrich, I., Godarova, A., Kotecki, M., Cochran, B.H., Spooner, E., Ploegh, H.L., Brummelkamp, T.R., Haploid genetic screens in human cells identify host factors used by pathogens. Science 326 (2009), 1231–1235.
6. Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K., Li, X.S., Woon, E.C., Yang, M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12 (2011), 463–469.
7. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 (2009), 739–744.
8. Epstein, A.C., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O'Rourke, J., Mole, D.R., Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001), 43–54.
9. Forbes, S.A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C.Y., Jia, M., Ewing, R., Menzies, A., et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38 (2010), D652–D657.
10. Haack, T.B., Rolinski, B., Haberberger, B., Zimmermann, F., Schum, J., Strecker, V., Graf, E., Athing, U., Hoppen, T., Wittig, I., et al. Homozygous missense mutation in BOLA3 causes multiple mitochondrial dysfunctions syndrome in two siblings. J. Inherit. Metab. Dis. 36 (2013), 55–62.
11. Hewitson, K.S., Liénard, B.M., McDonough, M.A., Clifton, I.J., Butler, D., Soares, A.S., Oldham, N.J., McNeill, L.A., Schofield, C.J., Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J. Biol. Chem. 282 (2007), 3293–3301.
12. Intlekofer, A.M., Dematteo, R.G., Venneti, S., Finley, L.W., Lu, C., Judkins, A.R., Rustenburg, A.S., Grinaway, P.B., Chodera, J.D., Cross, J.R., Thompson, C.B., Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab. 22 (2015), 304–311.
13. Jain, I.H., Zazzeron, L., Goli, R., Alexa, K., Schatzman-Bone, S., Dhillon, H., Goldberger, O., Peng, J., Shalem, O., Sanjana, N.E., et al. Hypoxia as a therapy for mitochondrial disease. Science 352 (2016), 54–61.
14. Kaelin, W.G. Jr., The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8 (2008), 865–873.
15. Kaelin, W.G. Jr., Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76 (2011), 335–345.
16. Koivunen, P., Lee, S., Duncan, C.G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J.A., Joensuu, P., Bergmann, U., Gross, S., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483 (2012), 484–488.
17. MacKenzie, E.D., Selak, M.A., Tennant, D.A., Payne, L.J., Crosby, S., Frederiksen, C.M., Watson, D.G., Gottlieb, E., Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 27 (2007), 3282–3289.
18. Manalo, D.J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B.D., Ye, S.Q., Garcia, J.G., Semenza, G.L., Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005), 659–669.
19. Maxwell, P.H., Ratcliffe, P.J., Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13 (2002), 29–37.
20. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999), 271–275.
21. Mayr, J.A., Zimmermann, F.A., Fauth, C., Bergheim, C., Meierhofer, D., Radmayr, D., Zschocke, J., Koch, J., Sperl, W., Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am. J. Hum. Genet. 89 (2011), 792–797.
22. Oldham, W.M., Clish, C.B., Yang, Y., Loscalzo, J., Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab. 22 (2015), 291–303.
23. Pollard, P.J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A., et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11 (2007), 311–319.
24. Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11 (2014), 783–784.
25. Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B., Gottlieb, E., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 (2005), 77–85.
26. Sun, R.C., Denko, N.C., Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 19 (2014), 285–292.
27. Szulwach, K.E., Li, X., Li, Y., Song, C.X., Wu, H., Dai, Q., Irier, H., Upadhyay, A.K., Gearing, M., Levey, A.I., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14 (2011), 1607–1616.
28. Tarhonskaya, H., Chowdhury, R., Leung, I.K., Loik, N.D., McCullagh, J.S., Claridge, T.D., Schofield, C.J., Flashman, E., Investigating the contribution of the active site environment to the slow reaction of hypoxia-inducible factor prolyl hydroxylase domain 2 with oxygen. Biochem. J. 463 (2014), 363–372.
29. Tarhonskaya, H., Rydzik, A.M., Leung, I.K., Loik, N.D., Chan, M.C., Kawamura, A., McCullagh, J.S., Claridge, T.D., Flashman, E., Schofield, C.J., Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat. Commun., 5, 2014, 3423.
30. Tchasovnikarova, I.A., Timms, R.T., Matheson, N.J., Wals, K., Antrobus, R., Göttgens, B., Dougan, G., Dawson, M.A., Lehner, P.J., GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. Science 348 (2015), 1481–1485.
31. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19 (2011), 17–30.